TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02465151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-based beverage
Description: protein-based beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-based beverage
Description: protein-based beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-based beverage
Description: protein-based beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-based beverage
Description: protein-based beverage
Study: NCT01043003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo Bilingual Breast Cancer Educational Intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: Support for caregiver

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial support for caregiver
Description: Support for caregiver

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Ancillary study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Ancillary study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: informational intervention
Description: Undergo evaluation sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: informational intervention
Description: Undergo evaluation sessions
Study: NCT04036851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Description: Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
Study: NCT02593799

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
Study: NCT00955890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane hydrochloride
Description: pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane hydrochloride
Description: pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane hydrochloride
Description: pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
Study: NCT03682185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-Control Condition
Description: This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Activity Intervention
Description: The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
Study: NCT02871167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Description: After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte/embryo freezing
Description: Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
Study: NCT00966147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing oxygen delivery .
Description: The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
Study: NCT00076310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m\^2 IV repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 IV every 21 days.
Study: NCT02609984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMB305
Description: A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: atezolizumab
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: IV Infusion
Study: NCT00398047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitadine and Hematopoietic Growth Factors
Description: Combination of Azacitadine and Hematopoietic Growth Factors
Study: NCT04816123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Donafenib
Description: Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
Study: NCT00161265

Intervention type: PROCEDURE
Intervention: tissue procurement
Description: tissue procurement
Study: NCT04074057

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Cardiac Rehab Classes
Description: conventional weekly CR programme lasting 8-12 sessions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Heart Track
Description: Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness.
Study: NCT03092817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
Study: NCT03998371

Intervention type: DIAGNOSTIC_TEST
Intervention: Low-coverage whole-genome sequencing of urine exfoliated cells
Description: The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low-coverage whole-genome sequencing of urine exfoliated cells
Description: The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
Study: NCT03092817

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose
Study: NCT00788242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium
Description: 20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Study: NCT03889145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine10mg
Description: Amlodipine 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine10mg
Description: Amlodipine 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study: NCT03454477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional open surgery
Description: conventional open surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic thyroidectomy
Description: endoscopic thyroidectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic thyroidectomy
Description: robotic thyroidectomy
Study: NCT04017117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh
Description: comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh
Description: comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
Study: NCT04588766

Intervention type: OTHER
Intervention: constipation group
Description: Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.

Intervention type: OTHER
Intervention: control group
Description: Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
Study: NCT05371106

Intervention type: OTHER
Intervention: exposure to mycotoxins
Description: self-report eating questionnaire
Study: NCT02570997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered.
Study: NCT02646956

Intervention type: OTHER
Intervention: sweeteners
Description: Participants tasted a variety of nutritive and nonnutritive sweeteners

Intervention type: OTHER
Intervention: sweeteners
Description: Participants tasted a variety of nutritive and nonnutritive sweeteners
Study: NCT00998842

Intervention type: DEVICE
Intervention: Recom Model 100
Description: Battery Operated, Ambulatory, Digital Wireless ECG Monitor System

Intervention type: DEVICE
Intervention: GE 5000 ECG Monitor System
Description: Wired ECG system
Study: NCT04478253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HypnoVR
Description: Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
Study: NCT00023998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo resection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study: NCT01456143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Microendoscopy (HRME)
Description: High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proflavine hemisulfate
Description: 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
Study: NCT00926432

Intervention type: DEVICE
Group type: OTHER
Intervention: EOS™ Acquisition
Description: Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.

Intervention type: DEVICE
Group type: OTHER
Intervention: EOS™ Acquisition
Description: Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
Study: NCT03964259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: Administration of post HDMTX intravenous fluids (IVF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluids
Description: Administration of post HDMTX intravenous fluids (IVF)
Study: NCT00986323

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature controlled Laminar Airflow (TLA)
Description: Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TLA
Description: Placebo TLA (without filtration and TLA function)
Study: NCT01249586

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-learning
Description: A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
Study: NCT03260764

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: long term Bifocal Spectacles
Description: wearing Bifocal Spectacles for one year
Study: NCT03038113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Modulator
Description: Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
Study: NCT00990613

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon IR
Description: A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon IR
Description: A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Study: NCT04032834

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask
Description: The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
Study: NCT00023998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01144377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546
Description: Administered subcutaneously
Study: NCT01144377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT03916640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADO09 formulation
Description: Subcutaneous injection of ADO09 formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection of 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 0.9% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symlin®
Description: Subcutaneous injection of pramlintide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin®
Description: Subcutaneous injection of human insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Subcutaneous injection of insulin lispro